Why This Analyst Upgraded Shares Of Cardiome To 'Speculative Buy'; Stock Skyrockets In Pre-Market
May 06, 2016 at 09:13 AM EDT
Mackie Research has upgraded CARDIOME PHARMA CORP (NASDAQ: CRME) to Speculative Buy from Hold on its recent licensing of Xydalba ...